Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Neuropathy, Painful
- Interventions
- Drug: Placebo
- Registration Number
- NCT01057693
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Brief Summary
Patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. All patients will receive pregabalin, and half of patients will receive placebo at some point during the study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 633
- Patients must have painful diabetic peripheral neuropathy and be receiving treatment for this condition.
- Patients with other pain conditions cannot participate.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description pregabalin (Lyrica) pregabalin (Lyrica) - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase SB Baseline, Week 19 (DB Phase) Mean pain score was defined as the mean of the last 7 daily diary pain ratings. Participants rated their DPN pain over the past 24 hours on an 11-point numeric rating scale ranging from 0 = no pain to 10 = worst possible pain. A rating of 1-3 was considered as mild pain; 4-6 = moderate pain; and 7-10 = severe pain. SB baseline refers to the last 7 pain diary entries up to and including Day 1.
- Secondary Outcome Measures
Name Time Method Weekly Mean Sleep Interference Score (Double-Blind Phase) DB Baseline, Week 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 Weekly mean sleep interference score was defined as the mean of the daily sleep interference diary ratings split into 7 day intervals. Participants rated how painful DPN has interfered with their sleep during the past 24 hours on an 11-point numeric rating scale ranging from 0 = does not interfere with sleep to 10 = completely interferes (unable to sleep due to pain).
Change From Single-Blind Baseline in Mean Pain Score at Week 6 During Single-Blind Phase SB Baseline, Week 6 (SB Phase) Mean pain score was defined as the mean of the last 7 daily diary pain ratings. Participants rated their DPN pain over the past 24 hours on an 11-point numeric rating scale ranging from 0 = no pain to 10 = worst possible pain. A rating of 1-3 was considered as mild pain; 4-6 = moderate pain; and 7-10 = severe pain. SB baseline refers to the last 7 pain diary entries up to and including Day 1.
Time to Loss of Pain Response (Double-Blind Phase) SB Baseline up to Week 19 Time to loss of pain response (based on the daily pain diary data) during the DB treatment phase was analyzed using survival analysis technique. Loss of pain response was defined as less than (\<) 15% pain response relative to the SB baseline. SB baseline refers to the last 7 pain diary entries up to and including Day 1.
Medical Outcomes Study -Sleep Scale (MOS-SS) (Double-Blind Phase) Week 19 Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance (range 0-100), snoring (range 0-100), awaken short of breath (SOB) or with headache (range 0-100), sleep adequacy (range 0-100), somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problems index (range 0-100). Except adequacy, optimal sleep and quantity, higher scores=more impairment.
Weekly Mean Pain Scores (Single-Blind Phase) Week 1, 2, 3, 4, 5, 6 Weekly mean pain score was defined as the mean of the daily diary pain ratings split into 7 day intervals. Participants rated their DPN pain over the past 24 hours on an 11-point numeric rating scale ranging from 0 = no pain to 10 = worst possible pain. A rating of 1-3 was considered as mild pain; 4-6 = moderate pain; and 7-10 = severe pain.
Percentage of Participants With At Least 30 Percent and 50 Percent Reduction in Mean Pain Score (Single-Blind Phase) Week 6 Mean pain score was defined as the mean of the last 7 daily diary pain ratings. Participants rated their DPN pain over the past 24 hours on an 11-point numeric rating scale ranging from 0 = no pain to 10 = worst possible pain. A rating of 1-3 was considered as mild pain; 4-6 = moderate pain; and 7-10 = severe pain. Percentage of participants who had at least 30% and 50% pain reduction from SB baseline to Week 6 is reported. SB baseline refers to the last 7 pain diary entries up to and including Day 1.
Endpoint Mean Sleep Interference Score (Single-Blind Phase) Week 6 Endpoint mean sleep interference score was defined as the mean of the last 7 sleep interference diaries while receiving SB treatment. Participants rated how painful DPN has interfered with their sleep during the past 24 hours on an 11-point numeric rating scale ranging from 0 = does not interfere to 10 = completely interferes (unable to sleep due to pain).
Hospital Anxiety and Depression Scale (HADS) (Single-Blind Phase) SB Baseline, Week 6 HADS: self-administered questionnaire, consists of 2 sub-scales; measuring anxiety (HADS-A), and depression (HADS-D). Each sub-scale consists of 7 items on which participants responded as to how each item applies to them on a 4-point scale ranging from 0 (no anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range for each sub-scale = 0 to 21, where higher score indicates more severe anxiety or depression.
Medical Outcomes Study -Sleep Scale (MOS-SS) (Single-Blind Phase) SB Baseline, Week 6 Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance (range 0-100), snoring (range 0-100), awaken short of breath (SOB) or with headache (range 0-100), sleep adequacy (range 0-100), somnolence (range: 0-100); sleep quantity (range: 0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problems index (range 0-100). Except adequacy, optimal sleep and quantity, higher scores=more impairment.
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) (Double-Blind Phase) Week 19 MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, and 9 item index measures of sleep disturbance provide composite scores: sleep problems index. Participants responded whether their sleep was optimal or not optimal by choosing yes or no.
Weekly Mean Sleep Interference Score (Single-Blind Phase) SB Baseline, Week 1, 2, 3, 4, 5, 6 Weekly mean sleep interference score was defined as the mean of the daily sleep interference diary ratings split into 7 day intervals. Participants rated how painful DPN has interfered with their sleep during the past 24 hours on an 11-point numeric rating scale ranging from 0 = does not interfere with sleep to 10 = completely interferes (unable to sleep due to pain). SB baseline refers to the last 7 pain diary entries up to and including Day 1.
Endpoint Mean Sleep Interference Score (Double-Blind Phase) Week 19 Endpoint mean sleep interference score was defined as the mean of the last 7 sleep interference diaries while receiving DB treatment. Participants rated how painful DPN has interfered with their sleep during the past 24 hours on an 11-point numeric rating scale ranging from 0 = does not interfere to 10 = completely interferes (unable to sleep due to pain).
Patient Global Evaluation of Study Medication (GESM) (Double-Blind Phase) Week 19 GESM: single-item, self-administered treatment satisfaction questionnaire. Participants answered "how would you rate the study medication you received for pain?" on a 7-point scale ranging from 1 (very satisfied) to 7 (very dissatisfied). Number of participants in each category are reported.
Weekly Mean Pain Scores (Double-Blind Phase) DB Baseline, Week 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 Weekly mean pain score was defined as the mean of the daily diary pain ratings split into 7 day intervals. Participants rated their DPN pain over the past 24 hours on an 11-point numeric rating scale ranging from 0 = no pain to 10 = worst possible pain. A rating of 1-3 was considered as mild pain; 4-6 = moderate pain; and 7-10 = severe pain. SB baseline refers to the last 7 pain diary entries up to and including Day 1. DB baseline refers to the last 7 pain diary entries up to and including DB Day 1.
Percentage of Participants With At Least 30 Percent and 50 Percent Reduction in Mean Pain Score (Double-Blind Phase) Week 19 Mean pain score was defined as the mean of the last 7 daily diary pain ratings. Participants rated their DPN pain over the past 24 hours on an 11-point numeric rating scale ranging from 0 = no pain to 10 = worst possible pain. A rating of 1-3 was considered as mild pain; 4-6 = moderate pain; and 7-10 = severe pain. Percentage of participants who had at least 30% and 50% pain reduction from SB baseline to Week 19 is reported.
Patient Global Impression of Change (PGIC) (Single-Blind Phase) Week 6 PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Number of participants in each category are reported.
Patient Global Impression of Change (PGIC) (Double-Blind Phase) Week 19 PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Number of participants in each category are reported.
Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) (Single-Blind Phase) SB Baseline, Week 6 MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awaken short of breath or with headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, and 9 item index measures of sleep disturbance provide composite scores: sleep problems index. Participants responded whether their sleep was optimal or not optimal by choosing yes or no.
Quality of Life Questionnaire- Diabetic Neuropathy (QOL-DN) (Double-Blind Phase) Week 19 QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. Consists of 5 domains: Physical functioning(Ph Fn)/large fiber (sum of item 8, 11, 13-15, 24, 27-35; range -4 to 56); Activities of daily living (sum of item 12, 22, 23, 25, 26; range 0 to 20); Symptoms (sum of item 1-7, 9; range 0 to 32); Small fiber (sum of item 10, 16, 17, 18; range 0 to 16); Autonomic (sum of item 19, 20, 21; range 0 to 12) and total QOL score (sum of items 1-35) range: -4 to 136. Higher score implied worse QOL.
Pain Visual Analog Scale (VAS) (Single-Blind Phase) SB Baseline, Week 6 Participants rated their pain on a 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm = no pain to 100 mm = worst possible pain.
Pain Visual Analog Scale (VAS) (Double-Blind Phase) Week 19 Participants rated their pain on a 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm = no pain to 100 mm = worst possible pain.
Brief Pain Inventory-Short Form (BPI-sf) (Single-Blind Phase) SB Baseline, Week 6 BPI-sf: self-administered questionnaire developed to assess severity, impact of pain on daily functions, consisted of 5 questions. Questions 1-4 measured the severity of pain based on pain experienced over the past 24-hours on an 11-point scale ranged from 0 (no pain) to10 (worst possible pain). Question 5: 7 item subsets that measured level of interference of pain on daily functions on an 11-point scale ranged from 0 (does not interfere) to 10 (completely interferes).
Hospital Anxiety and Depression Scale (HADS) (Double-Blind Phase) Week 19 HADS: self-administered questionnaire, consists of 2 sub-scales; measuring anxiety (HADS-A), and depression (HADS-D). Each sub-scale consists of 7 items on which participants responded as to how each item applies to them on a 4-point scale ranging from 0 (no anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score range for each sub-scale = 0 to 21, where higher score indicates more severe anxiety or depression.
Quality of Life Questionnaire- Diabetic Neuropathy (QOL-DN) (Single-Blind Phase) SB Baseline, Week 6 QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy. Consists of 5 domains: Physical functioning(Ph Fn)/large fiber (sum of item 8, 11, 13-15, 24, 27-35; range -4 to 56); Activities of daily living (sum of item 12, 22, 23, 25, 26; range 0 to 20); Symptoms (sum of item 1-7, 9; range 0 to 32); Small fiber (sum of item 10, 16, 17, 18; range 0 to 16); Autonomic (sum of item 19, 20, 21; range 0 to 12) and total QOL score (sum of items 1-35) range: -4 to 136. Higher score implied worse QOL.
Brief Pain Inventory-Short Form (BPI-sf) (Double-Blind Phase) Week 19 BPI-sf: self-administered questionnaire developed to assess severity, impact of pain on daily functions, consisted of 5 questions. Questions 1-4 measured the severity of pain based on pain experienced over the past 24-hours on an 11-point scale ranged from 0 (no pain) to10 (worst possible pain). Question 5: 7 item subsets that measured level of interference of pain on daily functions on an 11-point scale ranged from 0 (does not interfere) to 10 (completely interferes).
Patient Global Evaluation of Study Medication (GESM) (Single-Blind Phase) Week 6 GESM: single-item, self-administered treatment satisfaction questionnaire. Participants answered "how would you rate the study medication you received for pain?" on a 7-point scale ranging from 1 (very satisfied) to 7 (very dissatisfied). Number of participants in each category are reported.
Trial Locations
- Locations (163)
NeuroTrials Research, Incorporated
🇺🇸Atlanta, Georgia, United States
Research Protocol Management Specialists
🇺🇸Pittsburgh, Pennsylvania, United States
Carolina Pharmaceutical Research
🇺🇸Statesville, North Carolina, United States
TLM Medical Services, LLC
🇺🇸Columbia, South Carolina, United States
Dot Shuttleworth Centre for Diabetes
🇿🇦Durban, Overport, South Africa
Dr Jeevren Reddy's Surgery
🇿🇦Stanger, Kwazulu Natal, South Africa
Genova Clinical Research, Inc.
🇺🇸Tucson, Arizona, United States
Family Care Specialists, Inc.
🇺🇸Ocala, Florida, United States
Borgess Diabetes Center
🇺🇸Kalamazoo, Michigan, United States
Borgess Research Institute
🇺🇸Kalamazoo, Michigan, United States
William Beaumont Hospital
🇺🇸Troy, Michigan, United States
KMED Research
🇺🇸Saint Clair Shores, Michigan, United States
Physician's Surgery Center
🇺🇸Jackson, Mississippi, United States
CRC of Jackson
🇺🇸Jackson, Mississippi, United States
Randall T. Huling, Jr., MD, CPI
🇺🇸Olive Branch, Mississippi, United States
Lincoln Internal Medicine Associates
🇺🇸Lincoln, Nebraska, United States
University Diabetes & Endocrine Consultants
🇺🇸Chattanooga, Tennessee, United States
Foot and Ankle Clinic
🇺🇸West Jordan, Utah, United States
Neurology and Pain Clinic, LLC
🇺🇸Orangeburg, South Carolina, United States
Memphis Internal Medicine
🇺🇸Memphis, Tennessee, United States
Radiant Research Inc.
🇺🇸Greer, South Carolina, United States
SCRI Research Center
🇺🇸Germantown, Tennessee, United States
AM Diabetes & Endocrinology Center
🇺🇸Memphis, Tennessee, United States
University of Calgary
🇨🇦Calgary, Alberta, Canada
Sarah Cannon Research Institute
🇺🇸Jackson, Tennessee, United States
Instituto de Endocrinologia Diabetes y Metabolismo
🇵🇷Toa Baja, Puerto Rico
Bloemfontein Medi-Clinic
🇿🇦Bloemfontein, FREE State, South Africa
The Nerve and Muscle Center of Texas
🇺🇸Houston, Texas, United States
Elite Research Institute
🇺🇸Miami, Florida, United States
Rehabilitation Associates of Indiana
🇺🇸Indianapolis, Indiana, United States
CNRI-San Diego, LLC
🇺🇸San Diego, California, United States
San Diego Clinical Trials
🇺🇸San Diego, California, United States
Desert Endocrinology
🇺🇸Las Vegas, Nevada, United States
Office of Dr. Danka Michaels, MD
🇺🇸Las Vegas, Nevada, United States
Office of Stephen Miller, M.D.
🇺🇸Las Vegas, Nevada, United States
Community Research
🇺🇸Cincinnati, Ohio, United States
Paragon Research Center, LLC
🇺🇸San Antonio, Texas, United States
Alamo Clinical Research
🇺🇸San Antonio, Texas, United States
Cetero Research - San Antonio
🇺🇸San Antonio, Texas, United States
Convergys Clinical Research, Inc.
🇺🇸Anaheim, California, United States
University of Southern California, Keck School of Medicine, Department of Neurology
🇺🇸Los Angeles, California, United States
Richard S. Cherlin, MD
🇺🇸Los Gatos, California, United States
Northridge Neurological Research
🇺🇸Northridge, California, United States
Remek Research
🇺🇸Pomona, California, United States
MediSphere Medical Research Center, LLC
🇺🇸Evansville, Indiana, United States
Hometown Urgent Care and Research
🇺🇸Dayton, Ohio, United States
Providence Health Partners - Center for Clinical Research
🇺🇸Dayton, Ohio, United States
Baylor University Medical Center
🇺🇸Dallas, Texas, United States
University of Texas Southwestern Medical Center at Dallas
🇺🇸Dallas, Texas, United States
ClinRx Research LLC
🇺🇸Carrollton, Texas, United States
National Clinical Research - Norfolk, Inc.
🇺🇸Norfolk, Virginia, United States
Medical Group of Texas
🇺🇸Fort Worth, Texas, United States
MAPS Applied Research Center, Inc.
🇺🇸Edina, Minnesota, United States
Alpine Clinical Research Center, Inc.
🇺🇸Boulder, Colorado, United States
Medical Advanced Pain Specialists
🇺🇸Shakopee, Minnesota, United States
Heartland Research Associates, LLC
🇺🇸Wichita, Kansas, United States
Medical Advanced Pain Specialists (MAPS)
🇺🇸Edina, Minnesota, United States
Memorial Hospital of Rhode Island
🇺🇸Pawtucket, Rhode Island, United States
Center for Clinical Research, Inc.
🇺🇸San Francisco, California, United States
Harris and Associates MD, PC
🇺🇸Detroit, Michigan, United States
Veronique Sebastian, MD
🇺🇸Oklahoma City, Oklahoma, United States
Angelique Barreto, MD
🇺🇸Oklahoma City, Oklahoma, United States
Daniel B. Vine, MD
🇺🇸Salt Lake City, Utah, United States
Wasatch Clinical Research
🇺🇸Salt Lake City, Utah, United States
Jean Brown Research
🇺🇸Salt Lake City, Utah, United States
Arizona Research Center
🇺🇸Phoenix, Arizona, United States
Innovative Research of West Florida, Inc.
🇺🇸Clearwater, Florida, United States
Greystone Medical Research, LLC
🇺🇸Birmingham, Alabama, United States
Mountain View Clinical Research
🇺🇸Denver, Colorado, United States
East-West Medical Research Institute
🇺🇸Honolulu, Hawaii, United States
Oregon Health & Science University
🇺🇸Portland, Oregon, United States
Aurora Family Medicine Center, PC
🇺🇸Aurora, Colorado, United States
Clinical Research of West Florida, Inc.
🇺🇸Tampa, Florida, United States
Aurora Advanced Healthcare, Inc.
🇺🇸Milwaukee, Wisconsin, United States
Winnipeg Health Sciences Centre
🇨🇦Winnipeg, Manitoba, Canada
Neurology Clinic, PC
🇺🇸Northport, Alabama, United States
Horizon Clinical Research Associates, PLLC
🇺🇸Gilbert, Arizona, United States
Dedicated Clinical Research, Inc.
🇺🇸Goodyear, Arizona, United States
Novara Clinical Research
🇺🇸Mesa, Arizona, United States
Dedicated Clinical Research
🇺🇸Goodyear, Arizona, United States
Radiant Research, Inc.
🇺🇸Akron, Ohio, United States
Central Arkansas Research
🇺🇸Hot Springs, Arkansas, United States
Little Rock Diagnostic Clinic
🇺🇸Little Rock, Arkansas, United States
Providence Clinical Research
🇺🇸Burbank, California, United States
Healthcare Partners Medical Group
🇺🇸Los Angeles, California, United States
Valley Research
🇺🇸Fresno, California, United States
Center for United Research, Inc.
🇺🇸Lakewood, California, United States
Sierra Clinical Research
🇺🇸Roseville, California, United States
Neurological Research Institute
🇺🇸Santa Monica, California, United States
Apex Research Institute
🇺🇸Santa Ana, California, United States
Foothills Pain Management
🇺🇸West Covina, California, United States
Diablo Clinical Research, Inc.
🇺🇸Walnut Creek, California, United States
Chase Medical Research, LLC
🇺🇸Waterbury, Connecticut, United States
Metabolic Research Institute, Inc.
🇺🇸Boynton Beach, Florida, United States
Bradenton Research Center
🇺🇸Bradenton, Florida, United States
Meridien Research
🇺🇸Tampa, Florida, United States
Deerfield Beach Cardiology Research
🇺🇸Deerfield Beach, Florida, United States
MD Clinical
🇺🇸Hallandale Beach, Florida, United States
Gulfcoast Clinical Research Center
🇺🇸Fort Myers, Florida, United States
Laszlo J. Mate, MD
🇺🇸North Palm Beach, Florida, United States
Suncoast Clinical Research, Inc.
🇺🇸New Port Richey, Florida, United States
Compass Research, LLC
🇺🇸Orlando, Florida, United States
Renstar Medical Research
🇺🇸Ocala, Florida, United States
Palm Beach Neurological Center, Advanced Research Consultants, Inc.
🇺🇸Palm Beach Gardens, Florida, United States
Suncoast Clinical Research
🇺🇸Palm Harbor, Florida, United States
Neurology Clinical Research, Inc.
🇺🇸Sunrise, Florida, United States
Clinical Research of Central Florida
🇺🇸Winter Haven, Florida, United States
Columbus Research Foundation
🇺🇸Columbus, Georgia, United States
CPM Research Institute
🇺🇸Austell, Georgia, United States
Rockdale Medical Research Associates
🇺🇸Conyers, Georgia, United States
Prism Research Group
🇺🇸Rome, Georgia, United States
Valley Health Care
🇺🇸Rome, Georgia, United States
AMR Sakeena Research
🇺🇸Aurora, Illinois, United States
Advanced Clinical Research
🇺🇸Meridian, Idaho, United States
Chicago Research Center, Inc.
🇺🇸Chicago, Illinois, United States
American Medical Research, Inc.
🇺🇸Oak Brook, Illinois, United States
American Health Network
🇺🇸Greenfield, Indiana, United States
Kentucky Medical Research Center
🇺🇸Lexington, Kentucky, United States
Endocrinology Center of Southwest Louisiana
🇺🇸Lake Charles, Louisiana, United States
Clinical Research Center of Cape Cod, Inc.
🇺🇸Hyannis, Massachusetts, United States
Heartland Research, LLC
🇺🇸Lake Charles, Louisiana, United States
Primary Physician Care, LLC
🇺🇸Lake Charles, Louisiana, United States
Miray Medical Center
🇺🇸Brockton, Massachusetts, United States
Arthritis and Diabetes Clinic, Inc
🇺🇸Monroe, Louisiana, United States
MedVadis Research Corporation
🇺🇸Watertown, Massachusetts, United States
Michigan Head Pain and Neurological Institute
🇺🇸Ann Arbor, Michigan, United States
Troy Internal Medicine, PC
🇺🇸Troy, Michigan, United States
University of Missouri Healthcare/Cosmopolitan Diabetes and Endocrinology Center
🇺🇸Columbia, Missouri, United States
Mercy Health Research
🇺🇸Saint Louis, Missouri, United States
A & A Pain Institute of Saint Louis
🇺🇸Saint Louis, Missouri, United States
Clinvest
🇺🇸Springfield, Missouri, United States
Melinda A. Crockett-Maples
🇺🇸Marionville, Missouri, United States
Raleigh Neurology Associates, P.A.
🇺🇸Raleigh, North Carolina, United States
Sooner Clinical Research
🇺🇸Oklahoma City, Oklahoma, United States
Blair Orthopedic Associates, Inc.
🇺🇸Altoona, Pennsylvania, United States
Coastal Medical
🇺🇸East Greenwich, Rhode Island, United States
Altoona Center for Clinical Research
🇺🇸Duncansville, Pennsylvania, United States
Omega Medical Research
🇺🇸Warwick, Rhode Island, United States
Aiken Center for Clinical Research
🇺🇸Aiken, South Carolina, United States
ClinRx Research, LLC
🇺🇸Richardson, Texas, United States
Pioneer Research Solutions, Inc
🇺🇸Sugar Land, Texas, United States
L. Craig Larsen and Clark C. Larsen
🇺🇸Murray, Utah, United States
Aspen Clinical Research
🇺🇸Orem, Utah, United States
Neurological Associates, Incorporated
🇺🇸Henrico, Virginia, United States
Spokane Internal Medicine
🇺🇸Spokane, Washington, United States
The Ottawa Hospital, Riverside Campus - Riverside Professional Building
🇨🇦Ottawa, Ontario, Canada
Capital District Health Authority, QEII Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada
Winnipeg Regional Health Authority Sciences Centre Winnipeg
🇨🇦Winnipeg, Manitoba, Canada
Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
Ponce School of Medicine & Health Sciences
🇵🇷Ponce, Puerto Rico
Dr Makan's Rooms
🇿🇦Johannesburg, Gauteng, South Africa
Chelmsford Medical Centre
🇿🇦Durban, Kwazulu Natal, South Africa
Chris Hani Baragwanath Hospital
🇿🇦Soweto, Gauteng, South Africa
Randles Road Medical Centre
🇿🇦Durban, Kwa-zulu Natal, South Africa
Centre for Diabetes and Endocrinology
🇿🇦Houghton, Johannesburg, South Africa
Parklands Medical Centre
🇿🇦Overport, Kwazulu Natal, South Africa
102 Parklands Medical Centre
🇿🇦Overport, Durban, South Africa
Dr's Sauermann and Meyer
🇿🇦Polokwane, South Africa
Diabetes Care Centre
🇿🇦Pretoria, South Africa
Desert Endocrinology Clinical Research Center
🇺🇸Henderson, Nevada, United States
Clinical Pharmacology Study Group
🇺🇸Worcester, Massachusetts, United States
University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States
Radiant Research
🇺🇸Cincinnati, Ohio, United States